Byrne, Katelyn T.
Abramson Cancer Center · University of Pennsylvania
6 papers on CoChatORCID 0000-0002-2459-9041
Most cited papers
- Verified
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C., Kuri-Cervantes, L., Pampena, M. B., D’Andrea, K., et al. (2020) · Science
COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research
Cited by 1,509
- Verified
Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma
Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research
Cancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology Research
Cited by 459
- Verified
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
Padrón, L. J., Maurer, D. M., O’Hara, M. H., O’Reilly, E. M., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., et al. (2022) · Nature Medicine
Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers
Cited by 384
- Verified
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
O'Hara, M. H., O'Reilly, E. M., Varadhachary, G., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., Cabanski, C. R., et al. (2021) · The Lancet Oncology
Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers
Cited by 307
- Verified
CD40 stimulation obviates innate sensors and drives T cell immunity in cancer
Byrne, K. T., & Vonderheide, R. H. (2016) · Cell Reports
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 282
- Verified
Neoadjuvant Selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer
Byrne, K. T., Betts, C. B., Mick, R., Sivagnanam, S., Bajor, D. L., Laheru, D. A., Chiorean, E. G., O'Hara, M. H., Liudahl, S. M., Newcomb, C., et al. (2021) · Clinical Cancer Research
Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers
Cited by 199
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free